logo
Sign in

TLX Stock Price, Chart, Stats & News

Telix Pharmaceuticals Limited
Save
3.48B
Market cap
Current P/E
2000.00x
Forward P/E

TLX chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
50.74%
Operating margin
2.11%
Pretax margin
-0.66%
Net margin
-0.88%
Effective tax rate
-131.02%
ROA
-0.61%
ROE
-2.06%
D/E
1.26x
Interest coverage ratio
1.64x

TLX valuation

P/E
P/S
3.73x
P/B
7.28x
P/CF
-177.15x
P/FCF
-59.82x
P/OCF
-177.15x
PEG
2.25x
EV multiple
104.68x

About

Telix Pharmaceuticals Limited (TLX) is a commercial-stage biopharmaceutical entity specializing in the creation and distribution of advanced radiopharmaceuticals. Its core mission is to develop both diagnostic agents and therapeutic treatments for cancer and rare diseases across key international markets, including Australia, Belgium, Japan, Switzerland, and the United States. Among its currently available products, Telix offers Illuccix, designed for the management of prostate cancer, and TLX66-CDx, which serves as an imaging agent for osteomyelitis.

Similar securities

Based on sector and market capitalization

Report issue